SCA
EGRX

Secor Capital Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Secor Capital Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,028
Closed -$695K – 617
2018
Q3 		$695K Buy
10,028
+1,123
+13% +$85.1K 0.08% 282
2018
Q2 		$674K Buy
+8,905
New +$560K 0.06% 348

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Secor Capital Advisors's EGRX Position: Q4 2018 in Review

Secor Capital Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2018, closing a stake of 10,028 shares — an estimated $695K sold.

Secor Capital Advisors first reported a position in EGRX in Q2 2018 and held it in 2 quarters. The position peaked at $695K in Q3 2018. 182 funds tracked by Wall St. Rank hold EGRX as of Q4 2018.

  • Secor Capital Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Secor Capital Advisors sold 10,028 Eagle Pharmaceuticals, Inc. shares in Q4 2018, an estimated $695K.
  • Secor Capital Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2018 and held it in 2 quarters.
  • Secor Capital Advisors's Eagle Pharmaceuticals, Inc. position peaked at $695K in Q3 2018.
  • 182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2018.

Based on Secor Capital Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.